Natus Medical Inc (BABY) reported quarterly earnings results on Wednesday, Jul-20-2016. The company said it had a profit of $0.39 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $0.36. The company posted revenue of $96.00 million in the period, compared to analysts expectations of $92.71 million. The company’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.34 EPS.
Natus Medical Inc closed down -0.405 points or -1.00% at $40.25 with 2,20,593 shares getting traded on Monday. Post opening the session at $40.94, the shares hit an intraday low of $40.23 and an intraday high of $41.1899 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Apr 28, 2016, Robert A Gunst (director) sold 5,000 shares at $34.61 per share price. According to the SEC, on Apr 28, 2016, Doris Engibous (director) sold 5,000 shares at $32.68 per share price. On Apr 28, 2016, Kenneth M Traverso (VP/GM Newborn Care) sold 7,459 shares at $33.56 per share price, according to the Form-4 filing with the securities and exchange commission.
Natus Medical Incorporated (Natus) is a provider of newborn care and neurology healthcare products and services used for the screening diagnosis detection treatment monitoring and tracking of common medical ailments in newborn care hearing impairment neurological dysfunction epilepsy sleep disorders and balance and mobility disorders. The Company offers two product families: Neurology which includes products and services for diagnostic electroencephalography and long term monitoring intensive care unit monitoring electromyography sleep analysis intra-operative monitoring and diagnostic and monitoring transcranial doppler ultrasound technology; and Newborn Care which includes products and services for newborn care including hearing screening brain injury thermoregulation jaundice management and various disposable products as well as products for diagnostic hearing assessment for children through adult populations and others.